Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: Sabcomeline (SB-202026)
Mode of action: M1 agonist
Phase: Inactive
Note: Previously used in Alzheimer's disease

Useful Links:

Loudon RP, Perussia B, Benovic JL. Differentially regulated expression of the G-protein-coupled receptor kinases, betaARK and GRK6, during myelomonocytic cell development in vitro. Blood . 1996 Dec 15 ; 88(12):4547-57. Abstract

Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol . 2006 May 16 ; 47(10):1919-26. Abstract

Hatcher JP, Loudon JM, Hagan JJ, Clark MS. Sabcomeline (SB- 202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Psychopharmacology (Berl). 1998 Aug;138(3-4):275-82. Abstract

Harries MH, Samson NA, Cilia J, Hunter AJ. Related The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Br J Pharmacol. 1998 May;124(2):409-15. Abstract

Bromidge SM, Brown F, Cassidy F, Clark MS, Dabbs S, Hadley MS, Hawkins J, Loudon JM, Naylor CB, Orlek BS, Riley GJ. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo [2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. J Med Chem. 1997 Dec 19;40(26):4265-80. Abstract

July 27, 2016
SRF News
SRF Comments
Text Size
Reset Text Size

Check out our upcoming webinar, Studying Psychosis in 22q11 Deletion Syndrome, Thursday, July 28, 2016, 1-2:30 p.m. EDT.

See our recent webinar, The Baby and the Bathwater: Signal and Noise in Psychiatric Neuroimaging.
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright